

DAFTAR PUSTAKA

1. Younossi Z, Koenig A, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64(1):73-84.
2. Bashiardes S, Shapiro H, Rozin S, et al. Non-alcoholic fatty liver and the gut microbiota. *Mol metabol*. 2016;5(9):782-94.
3. Marzio H, Dina L, Fenkel J. Concepts and treatment approaches in nonalcoholic fatty liver disease. *Adv Hepatol*. 2014;2014.
4. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *Jama-j am med assoc*. 2015;313(22):2263-73.
5. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism*. 2016;65(8):1038-48.
6. He X, Ji G, Jia W, et al. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomics. *Int j mol sci*. 2016;17(3):300.
7. Quigley E, Stanton C, Murphy E. The gut microbiota and the liver. Pathophysiological and clinical implications. *J hepatol*. 2013;58(5):1020-7.
8. Zhu L, Baker S, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. *Hepatology*. 2013;57(2):601-9.
9. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology*. 2016;63(3):764-75.
10. Mouzaki M, Comelli E, Arendt B, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology*. 2013;58(1):120-7.
11. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases. American College of Gastroenterology and American Gastroenterology Association. *Hepatology*. 2018;55(6):2005-23.

12. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic fatty liver disease: Evolving paradigms. *World j gastroenterol.* 2017;23(36):6571.
13. Saltzman ET, Palacios T, Thomsen M, et al. Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease. *Front microbiol.* 2018;9:61.
14. Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. *Sci Rep UK.* 2015;5(1):8096.
15. Alam S, Mustafa G, Alam M, et al. Insulin resistance in development and progression of nonalcoholic fatty liver disease. *World j gastrointest pathophysiol.* 2016;7(2):211.
16. Da Silva HE, Teterina A, Comelli EM, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. *Sci Rep UK.* 2018;8(1):1-12.
17. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. *Gastroenterology.* 2019;156(5):1264-81. e4.
18. Swidsinski A, Loening-Baucke V, Lochs H, et al. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. *World j gastroenterol.* 2005;11(8):1131.
19. Sina C, Lipinski S, Gavrilova O, et al. Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice. *Gut.* 2013;62(4):520-30.
20. Huttenhower C, Gevers D, Knight R, et al. Structure, function and diversity of the healthy human microbiome. *Nature.* 2012;486(7402):207.
21. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature.* 2010;464(7285):59.
22. Sekirov I, Russell S, Antunes L, et al. Gut microbiota in health and disease. *Physiol rev.* 2010;90(3):859-904.
23. Gangarapu V, Yıldız K, İnce AT, et al. Role of gut microbiota: obesity and NAFLD. *Turk j gastroenterol.* 2014;25(2):133-40.

24. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. *Gastroenterology*. 2014;146(6):1449-58.
25. Jandhyala S, Talukdar R, Subramanyam C, et al. Role of the normal gut microbiota. *World j gastroenterol*. 2015;21(29):8787.
26. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. *Mol aspects med*. 2013;34(1):39-58.
27. Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. *Clin Gastroenterol Hepatol*. 2019;17(2):296-306
28. Bataller R, Brenner D. Liver fibrosis. *J clin invest*. 2005;115(2):209-18.
29. Mizrahi-Man O, Davenport ER, Gilad Y. Taxonomic classification of bacterial 16S rRNA genes using short sequencing reads: evaluation of effective study designs. *PLoS one*. 2013;8(1):e53608.
30. Pan WH, Yeh WT. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. *Asia Pac j clin nutr*. 2008;17(3):370.
31. Soelistijo S, Lindarto D, Decroli E, et al. Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 Dewasa di Indonesia 2019. PB PERKENEI Jakarta. 2019.
32. Aman A, Soewondo P, Soelistijo S. Pedoman Pengelolaan Dislipidemia di Indonesia 2019. PB PERKENEI Jakarta. 2019.
33. Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. *Cell metab*. 2019;30(3):607.
34. Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines. *J gastroenterol hepatol*. 2007;22(6):778-87.

35. Ryoo JH, Suh YJ, Shin HC, et al. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. *J gastroenterol hepatol.* 2014;29(11):1926-31.
36. Loomba R, Sanyal AJ. The global NAFLD epidemic. *Nature rev Gastroenterol hepatol.* 2013;10(11):686-90.
37. Wu KT, Kuo PL, Su SB, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. *J clin lipidol.* 2016;10(2):420-5. e1.
38. Bastian WP, Hasan I, Lesmana CRA, et al. Gut Microbiota profiles in nonalcoholic fatty liver disease and its possible impact on disease progression evaluated with transient elastography: Lesson learnt from 60 cases. *Case rep gastroenterol.* 2019;13(1):125-33.
39. Castaner O, Goday A, Park YM, et al. The gut microbiome profile in obesity: a systematic review. *Int j endocrinol.* 2018;2018.
40. Million M, Maraninchi M, Henry M, et al. Obesity-associated gut microbiota is enriched in *Lactobacillus reuteri* and depleted in *Bifidobacterium animalis* and *Methanobrevibacter smithii*. *Int j obes.* 2012;36(6):817-25



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
 UNIVERSITAS HASANUDDIN
 FAKULTAS KEDOKTERAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 KOMITE ETIK PENELITIAN KESEHATAN





Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081225704670 e-mail : agussalimbukhari@yahoo.com

REKOMENDASI PERSETUJUAN ETIK

Nomor : 587 / H4.8.4.5.31 / PP36-KOMETIK / 2018

Tanggal: 30 Agustus 2018

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH18040226	No Sponsor Protokol	
Peneliti Utama	Dr.dr.Nu'man A.S. Daud,Sp.PD,K-GEH,FINASIM	Sponsor	Pribadi
Judul Peneliti	Metagenomik Diversitas Mikrobiom dari Feses Pasien Perlemakan Hati Non Alkoholik		
No Versi Protokol	2	Tanggal Versi	13 Agustus 2018
No Versi PSP	2	Tanggal Versi	13 Agustus 2018
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo dan Laboratorium HUM-RC FKUH Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 30 Agustus 2018 sampai 30 Agustus 2019	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	Tanggal
Sekretaris Komisi Etik Penelitian	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	Tanggal

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan